Novartis Q1 results
This article was originally published in The Tan Sheet
Executive Summary
Strong first-quarter sales of cough/cold products including Theraflu were "partially offset by a shrinking smoking-cessation market in Europe," Novartis said in an April 21 release. The firm's net consumer sales rose 9% to $1.7 bil. due in part to double-digit growth in the medical nutrition and OTC drug businesses; increased volumes accounted for 5% of the growth, currency exchange for 3% and acquisitions for 1%. Novartis' overall sales advanced 11% to $7.3 bil. with net earnings up 16% to $1.4 bil...
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.